Expanding the reaction toolbox for nanoscale direct-to-biology PROTAC synthesis and biological evaluation

Rebecca Stevens, Harry J. Shrives, Jenni Cryan, Diana Klimaszewska, Peter Stacey, Glenn A. Burley, John D. Harling, David J. Battersby and Afjal H. Miah

RSC Med. Chem., 2025, 16, 1141
DOI: 10.1039/D4MD00760C

Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs

André T. S. Vicente, Sara P. S. P. Moura and Jorge A. R. Salvador

Commun Chem, 2025, 8
DOI: 10.1038/s42004-025-01598-9

Protein Degradation in Focus

David Zollman and Kirsten McAulay

Nat Chem Biol, 2024, 20, 1559
DOI: 10.1038/s41589-024-01757-4

In situ construction of intracellular supramolecular assemblies as an alternative strategy for protein degradation

Xiaoqian Hu, Qingxin Yao, Xiaobo Wu, Jiali Chen, Ruijia Zhang, Yan Zhao and Yuan Gao

Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-61175-5

Recent developments in bioconjugation: From strategies to design and clinical applications

Faezeh Samieipour, Hassan Dianat-Moghadam and Hossein Khanahmad

Biomedicine & Pharmacotherapy, 2025, 192, 118593
DOI: 10.1016/j.biopha.2025.118593

Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening

Andreas Holmqvist, Nur Mehpare Kocaturk, Christina Duncan, Jennifer Riley, Steven Baginski, Graham Marsh, Joel Cresser-Brown, Hannah Maple, Kristiina Juvonen, Gajanan Sathe, Nicola Morrice, Calum Sutherland, Kevin D. Read and William Farnaby

Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-63928-8

Factors to Consider for Synthesis in 1536-Well Plates─An Amide Coupling Case Study for PROTAC Synthesis

Rebecca Stevens, Harry E. P. Palmer, Afjal H. Miah and Glenn A. Burley

J. Org. Chem., 2025, 90, 2192
DOI: 10.1021/acs.joc.4c02456

Accelerated synthesis of immunomodulatory imide drugs and their derivatives via continuous flow chemistry

Tianyi Hou, Junrong Huang, Yongheng Li, Yuxiang Zhu, Hengzhi You and Fen-Er Chen

Commun Chem, 2026
DOI: 10.1038/s42004-026-01956-1

Collaborative GSK–University of Strathclyde doctoral research and training programmes: Transforming approaches to industry–academia engagement

Laura C. Paterson, Philip G. Humphreys, Henry A. Kelly and William J. Kerr

Drug Discovery Today, 2024, 29, 104162
DOI: 10.1016/j.drudis.2024.104162

Advances in Targeted Therapies for Inflammatory Diseases and Cancer: Exploring Cellular Mechanisms and Therapeutic Strategies

Robert B. Kargbo

ACS Med. Chem. Lett., 2024, 15, 758
DOI: 10.1021/acsmedchemlett.4c00182

E3 ubiquitin ligase TRIM31: A potential therapeutic target

Nian-Hua Deng, Zhen Tian, Ying-Jiao Zou and Shou-Bo Quan

Biomedicine & Pharmacotherapy, 2024, 176, 116846
DOI: 10.1016/j.biopha.2024.116846

DNA Tetrahedron-Driven Multivalent Proteolysis-Targeting Chimeras: Enhancing Protein Degradation Efficiency and Tumor Targeting

Shiqing Li, Tao Zeng, Zhixing Wu, Jiabao Huang, Xiuping Cao, Yana Liu, Shiyan Bai, Qi Chen, Chunsen Li, Chunhua Lu and Huanghao Yang

J. Am. Chem. Soc., 2025, 147, 2168
DOI: 10.1021/jacs.4c16438

Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research

Meichen Pan, Zhongliang Fu, Hongwei Hou, Chunrong Yang and Jinghong Li

Small Methods, 2025, 9
DOI: 10.1002/smtd.202500402

Alkyne Two-Phase Strategy: Rapid Generation of TK-285-Derived PROTACs as BRD4 Degraders

Hiroyuki Yamakoshi, Ryo Watanabe, Ryosuke Segawa, Ryosuke Ishihara, Ryo Tachibana, Genki Kudo, Shota Nagasawa, Satoshi Yamanaka, Ayano Ito, Hiroyuki Takeda, Tatsuya Sawasaki, Ryunosuke Yoshino, Takatsugu Hirokawa, Takayuki Doi, Noriyasu Hirasawa and Yoshiharu Iwabuchi

J. Med. Chem., 2026
DOI: 10.1021/acs.jmedchem.5c03771

Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation

Junyi Zhao, Hongzhen Chen and Chao Liang

Biomark Res, 2025, 13
DOI: 10.1186/s40364-025-00826-7

Lessons learned in linking PROTACs from discovery to the clinic

Andy Pike, Esther C. Y. Lee, Iacovos N. Michaelides, Markus Schade, Ankit Sharma, James S. Scott and Abhishek Srivastava

Nat Rev Chem, 2025, 10, 117
DOI: 10.1038/s41570-025-00784-6

Accelerating the Discovery of Targeted Protein Degraders: Advances in Synthetic Methodologies and Screening Tactics

Baoli Ding, Xiaotong Chen, Yulu Chen, Ji Cao, Bo Yang, Li Jiang and Cheng‐Liang Zhu

Chemistry A European J, 2026
DOI: 10.1002/chem.202503641

Next steps for targeted protein degradation

Mackenzie W. Krone and Craig M. Crews

Cell Chemical Biology, 2025, 32, 219
DOI: 10.1016/j.chembiol.2024.10.004

Marine‐Derived Molecular Glue Degraders: A New Frontier in Targeted Protein Degradation for Treatment of Multi‐Factorial Diseases

Vajagathali Mohammed, B. Haridevamuthu, Kathiravan Muthu Kumaradoss, S. Karthick Raja Namasivayam and Jesu Arockiaraj

Biotech and App Biochem, 2025
DOI: 10.1002/bab.70055

Recent advances in targeting protein degradation for tumor immunotherapy

Shuai Li, Yushan Jin, Huanhuan Wu, Hong Yuan and Jingyuan Zhao

J Hematol Oncol, 2025, 19
DOI: 10.1186/s13045-025-01765-4